

**Presentation 10 – Mariana Morris**

**Gulf War-related Research at  
Wright State University**

Mariana Morris, Ph.D.  
Professor and Chair  
Department of Pharmacology and Toxicology



**The Mission:**

To understand the basis of toxicity from environmental, chemical and life-style interactions and to use this to study and develop countermeasures



## Research Advisory Committee on Gulf War Veterans' Illnesses

### August 15, 2006

## VA tests remedies for Gulf illness

Dayton, Cincinnati centers each have trial programs under way

By KEVIN LAMB  
*Dayton Daily News*

CINCINNATI — Gulf War veterans experiencing the joint pain, muscle aches, fatigue, concentration difficulties and rashes that have been termed Gulf War syndrome are invited to join the Cincinnati VA Medical Center's demonstration treatment program for veterans with these symptoms. Cincinnati is one of five U.S. sites conducting the one-year treatment trial, which will become a model for further programs if it is effective.

The individualized treatment includes physical therapy, therapeutic exercise, access to a support group and treatment for physical symptoms or underlying mental disorders such as depression or post-traumatic stress syndrome. For information, call Carolyn Homan toll-free at (888) 865-3321 or directly at (513) 861-3119, extension 4265.

The Cincinnati trial is different from two other trials for Gulf War syndrome for which the Dayton VA Center is among 30 participating centers.

One trial is to determine whether exercise alone or in combination with psychological cognitive behavioral therapy can diminish the severity of symptoms, and the other will test whether an antibiotic can effectively treat the symptoms. Call 398-6511, Ext. 1212, for information on the Dayton trials.

# COUNTERTOX

## Research Partners

- ◆ Boonshoft School of Medicine
  - Pharmacology and Toxicology
  - Biochemistry and Molecular Biology
- ◆ Wright-Patterson AFB, Air Force Research Laboratory
- ◆ Dayton VA Medical Center
- ◆ Battelle Biomedical Research Center
- ◆ Rea Clinic
- ◆ Cenomed Inc


## **Core Research Facilities**

- ◆ Center for Genomics
- ◆ Proteomics Analysis Laboratory
- ◆ Integrative Cardiovascular Laboratory (ICL)
- ◆ Chemical Warfare Agent Research Facility (CWF)
- ◆ Biosafety Laboratories
- ◆ Animal Resources Laboratory
- ◆ Magnetic Resonance Laboratory

## **Major Research Topics: Sarin Exposure**

- ◆ Behavior
- ◆ Autonomic neural function
- ◆ Genomic biomarkers
- ◆ Chemical sensitivity in humans and sarin metabolism
- ◆ Proteomic biomarkers



## Experimental Stress Model




## METHODS

### Stress & Sarin Exposure

- ◆ Mice exposed to intermittent shaker stress for 7 days
- ◆ Sarin was injected sc for 3 days (64  $\mu\text{g}/\text{kg}$ , 0.4 $\times$ LD<sub>50</sub>)
- ◆ Groups: Control, Sarin, Sarin & Stress, Stress
- ◆ Evidence for adrenal dysfunction, altered fear potentiation and self-mutilation




## Sarin and Stress Adrenal Function



Lucot et. al


## Sarin & Stress Evidence for Self-Mutilation



Sarin & stress produced self mutilation in a subset of mice (~ 30%). This was not observed in the other groups.

Lucot et. al

## Sarin and Fear Potentiation of Startle Response



Behavioral response prevented in sarin treated mice


Lucot et. al

## METHODS


### Sarin & Autonomic Function

- ◆ Mice with telemetric carotid catheters
- ◆ Sarin was administered sc for 2 days (8  $\mu\text{g}/\text{kg}$ , 0.05LD<sub>50</sub>)
- ◆ Cardiovascular parameters measured from 1 to 10 weeks after sarin
- ◆ Evidence for delayed autonomic dysfunction, similar to that seen with heart failure

## Delayed Effect of Sarin on Heart Rate Variance and Frequency Domains



## Low Dose Sarin Produces Delayed Changes in Brainstem Amine Function






## Gene Array Analysis




### **Gene Array Method**

- ◆ Affymetrix GeneChip® (oligonucleotide based array)
- ◆ Mouse genome U74A (v2) chip
- ◆ Microarray Suite (v 5.0)
- ◆ Affymetrix Data Mining Tool (v 2.0)
- ◆ GeneSpring (v 6.1)
- ◆ PathwayAssist (v 2.5)

## Experimental Protocol Low Dose Sarin on Genomic Expression



## Low Dose Sarin Brain and Blood Cholinesterase




## **Data Mining (GeneSpring)**

- ◆ Raw intensity and flags (P, M & A) from DMT
- ◆ Normalize all 14 chips to the median of controls
- ◆ Eliminate genes that were not present in at least 2 samples (6,388 in cortex & 6,070 in hypothalamus)
- ◆ Select genes increased or decreased (two-fold) Hcompared to control (70 in cortex & 51 in the hypothalamus)


## **Low Dose Sarin Effect on Cortex and Hypothalamus**

<b>Tissue</b>	<b>Increase</b>	<b>Decrease</b>
Cortex	51	19
Hypothalamus	31	20

## Genomics: Comparison of Hypothalamus to Cortex




## Classes of Genomic Changes Hypothalamic Increases



## Sarin Increases Hypothalamic:

- ◆ Glial cell derived neurotrophic factor (GDNF)
- ◆ Serotonin transporter (SLC6A4)
- ◆ Tyrosine/Tryptophan activation protein (YWHAQ)
- ◆ PG F2 receptor negative regulator (PTGFRN)
- ◆ Doublecortin (DCX)

## Classes of Genomic Changes Hypothalamic Decreases



- ◆ Enzymes \*
- ◆ Nucleic acid binding \*
- ◆ Unclassified \*
- ◆ Transport \*
- ◆ Cell cycle \*
- ◆ Signal transduction
- ◆ Other groups
- ◆ Apoptosis
- ◆ Structural protein

## **Sarin Decreases Hypothalamic:**

- ◆ PG D2 synthase (PTGDS)
- ◆ Voltage gated K<sup>+</sup> channel (KCND2)
- ◆ Artemin of Glial cell line-Derived Neurotrophic Factor (GDNF) family (ARTN)
- ◆ Ankyrin repeat & SOCS box containing (ASB3)


## **Low Dose Sarin & Genomics CONCLUSIONS**

- ◆ There are brain changes in genetic expression at a sarin dose that does not change AChE activity
- ◆ Cortex and hypothalamus respond differently to acute sarin exposure.
- ◆ Detailed analysis (genomic and proteomic) will provide mechanistic insights into low dose sarin toxicity

## Chemical Metabolism in Humans with Chemical Sensitivity

- ◆ Hypothesis: Chemical sensitivity is linked to deficiencies in scavenging enzymes.
- ◆ Corollary: Chemically sensitive individuals should have altered levels of scavenging enzymes

Alter et. al



## Activities Measured

Formaldehyde  $\longrightarrow$  Formate

- 1) Aldehyde Dehydrogenase (ALD): NAD
- 2)  $\alpha$ -Alcohol Dehydrogenase ( $\alpha$ ADH): NAD, GSH

Paraoxon  $\longrightarrow$  P - Nitrophenol + Diethyl Phosphate

Paraoxonase:  $\text{Ca}^{2+}$

Phenyl Acetate  $\longrightarrow$  Phenol + Acetate

Arylesterase:  $\text{Ca}^{2+}$

## Sample Population


- ◆ Blood samples from chemically sensitive (formaldehyde or organophosphate) persons
- ◆ Rea Clinic, Dallas, TX
- ◆ Experiments were not performed directly with humans





## Abbreviations

- ◆ Chi Alcohol Dehydrogenase: xADH
- ◆ Aldehyde Dehydrogenase: ALD
- ◆ Paraoxonase: PON
- ◆ Arylesterase: AE
- ◆ Red blood cell: r
- ◆ White blood cell: w
- ◆ Serum: s
- ◆ Organophosphate: OP

Gender Dependence of Activity





## **Biomarkers for Chemical Sensitivity**

- ◆ NO age dependence
- ◆ NO gender dependence
- ◆ Ethnic dependence – little data
- ◆ BIOCHEMICAL MARKERS FOR ORGANOPHOSPHATE AND FORMALDEHYDE SENSITIVITY

